Litcius/Paper detail

Surufatinib — a novel oral agent for neuroendocrine tumours

Anna Koumarianou, Gregory Kaltsas

2020Nature Reviews Endocrinology20 citationsDOI

Topics & Concepts

MedicineAngiogenesisNeuroendocrine tumorsImmune systemCancer researchLungTyrosine-kinase inhibitorTyrosine kinaseNeuroendocrine tumourPancreasInternal medicineOncologyImmunologyReceptorCancerNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesPancreatic and Hepatic Oncology Research
Surufatinib — a novel oral agent for neuroendocrine tumours | Litcius